BG63103B1 - Използуване на алендронат за профилактика на остеопороза - Google Patents

Използуване на алендронат за профилактика на остеопороза Download PDF

Info

Publication number
BG63103B1
BG63103B1 BG102060A BG10206097A BG63103B1 BG 63103 B1 BG63103 B1 BG 63103B1 BG 102060 A BG102060 A BG 102060A BG 10206097 A BG10206097 A BG 10206097A BG 63103 B1 BG63103 B1 BG 63103B1
Authority
BG
Bulgaria
Prior art keywords
alendronate
osteoporosis
bone
aln
placebo
Prior art date
Application number
BG102060A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102060A (en
Inventor
Ashley Yates
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG102060A publication Critical patent/BG102060A/xx
Publication of BG63103B1 publication Critical patent/BG63103B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG102060A 1995-06-02 1997-11-20 Използуване на алендронат за профилактика на остеопороза BG63103B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45819595A 1995-06-02 1995-06-02
PCT/US1996/007912 WO1996038156A1 (en) 1995-06-02 1996-05-29 Use of alendronate for the prevention of osteoporosis

Publications (2)

Publication Number Publication Date
BG102060A BG102060A (en) 1998-07-31
BG63103B1 true BG63103B1 (bg) 2001-04-30

Family

ID=23819759

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102060A BG63103B1 (bg) 1995-06-02 1997-11-20 Използуване на алендронат за профилактика на остеопороза

Country Status (21)

Country Link
EP (1) EP0828496A1 (ko)
JP (1) JPH10506648A (ko)
KR (1) KR19990022436A (ko)
CN (1) CN1192685A (ko)
AU (1) AU709196B2 (ko)
BG (1) BG63103B1 (ko)
BR (1) BR9609020A (ko)
CA (1) CA2222318A1 (ko)
CZ (1) CZ381197A3 (ko)
EA (1) EA000677B1 (ko)
EE (1) EE03306B1 (ko)
HU (1) HUP9900659A3 (ko)
IL (1) IL118422A0 (ko)
IS (1) IS4617A (ko)
NO (1) NO975527D0 (ko)
NZ (1) NZ308935A (ko)
PL (1) PL323669A1 (ko)
SK (1) SK159597A3 (ko)
TR (1) TR199701482T1 (ko)
WO (1) WO1996038156A1 (ko)
ZA (1) ZA964465B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
KR102472749B1 (ko) * 2022-01-18 2022-12-02 주식회사 위엔씨 유해가스제거 및 항균탈취기능을 함유한 흡착소재 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations

Also Published As

Publication number Publication date
CA2222318A1 (en) 1996-12-05
AU5882496A (en) 1996-12-18
NO975527L (no) 1997-12-01
NZ308935A (en) 2000-07-28
IS4617A (is) 1997-11-19
AU709196B2 (en) 1999-08-26
KR19990022436A (ko) 1999-03-25
SK159597A3 (en) 1998-06-03
EP0828496A1 (en) 1998-03-18
HUP9900659A2 (hu) 2001-04-28
BR9609020A (pt) 1999-07-06
BG102060A (en) 1998-07-31
CN1192685A (zh) 1998-09-09
HUP9900659A3 (en) 2002-12-28
TR199701482T1 (xx) 1998-03-21
PL323669A1 (en) 1998-04-14
EA000677B1 (ru) 2000-02-28
CZ381197A3 (cs) 1998-06-17
NO975527D0 (no) 1997-12-01
IL118422A0 (en) 1996-09-12
ZA964465B (en) 1996-12-11
JPH10506648A (ja) 1998-06-30
WO1996038156A1 (en) 1996-12-05
EE03306B1 (et) 2000-12-15
EA199700449A1 (ru) 1998-06-25

Similar Documents

Publication Publication Date Title
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
JP2004531468A5 (ko)
EA000964B1 (ru) Способ лечения или предупреждения остеопороза
US5804570A (en) Method of lessening the risk of non-vertebral bone fractures
US20110166234A1 (en) Medicinal product and treatment
BG63103B1 (bg) Използуване на алендронат за профилактика на остеопороза
US20020169148A1 (en) Use of alendronate for the prevention of osteoporosis
Iba et al. A significant improvement in lower limb pain after treatment with alendronate in two cases of Camurati–Engelmann disease
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
KR19980702209A (ko) 척추 골절의 위험을 경감시키는 방법
KR20230018481A (ko) 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여
AU5677896A (en) Prevention of tooth loss by the administration of alendronate or its salts
GB2197198A (en) Analgesic preparations
TW201105332A (en) Agent for preventing forearm bone fracture which comprises eldecalcitol
Standard Pr TEVA-RISEDRONATE
TW201105333A (en) Agent for preventing non-traumatic vertebral fracture in severe osteoporosis patients which comprises eldecalcitol
Sack Fighting the fracture cascade: evaluation and management of osteoporotic fractures
Zahid et al. Efficacy of Bisphosphonates and Recombinant Parathyroid Hormone in Treatment of Osteoporosis in Pakistan
EP0691814B1 (en) Method and composition for treatment of osteoporosis
CN100560075C (zh) 调节脂类代谢的药物
WO2020118442A1 (en) Methods for treating heterotopic ossification
CN1187130A (zh) 用二磷酸盐预防与免疫抑制疗法有关的骨损失
Sirsikar et al. Prevention and Management of Postmenopausal Osteoporosis
MXPA97009906A (en) Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres
Sutcliffe The benefits of medicating less often